Guardant Health, Inc.: Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal blood test to help guide treatment decisions in colorectal cancer
Trial will evaluate use of circulating tumor DNA to guide chemotherapy treatment decisions following surgery for stage II-III colorectal cancer patients based on test results for minimal residual